Clinical Trials Logo

Carcinoid Tumor clinical trials

View clinical trials related to Carcinoid Tumor.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05061784 Completed - Thymic Carcinoid Clinical Trials

Routine Transcervical Thymectomy in MEN-1 Patients

Start date: July 14, 2021
Phase:
Study type: Observational

A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.

NCT ID: NCT04197310 Completed - Clinical trials for Neuroendocrine Tumors

Cabozantinib and Nivolumab for Carcinoid Tumors

Start date: December 26, 2019
Phase: Phase 2
Study type: Interventional

This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. - Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

NCT ID: NCT03723499 Completed - Carcinoid Tumor Clinical Trials

Endoscopic Treatment of Bronchial Carcinoid Tumors

Start date: November 1995
Phase:
Study type: Observational

Carcinoid tumors of the lung are considered to be a low-grade malignancy. Surgical resection is considered the standard approach. Recent data has shown that a complete endoscopic treatment could be considered. An endoscopic treatment is can be a alternative to invasive surgery.

NCT ID: NCT03722511 Completed - Diarrhea Clinical Trials

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

Primary Objective: To assess how an amino acid based medical food (Enterade®) helps maintain the intestine's ability to absorb and retain fluids, leading to a reduction in diarrhea due to Neuroendocrine Tumors (NET) and/or Carcinoid Syndrome. This improvement in the absorption will be assessed in part by evaluating changes in average daily stool frequency from baseline in patients receiving Enterade®. Each subject serves as his or her own control. Secondary Objectives: - To assess subject reported health-related quality of life in subjects before and after compound administration. - To characterize the side effect profile and tolerability of Enterade® as measured by the number of total 8-oz Enterade® bottles consumed throughout the trial, and average drinks per day. - To evaluate changes in serum electrolytes before and after administration of Eenterade®. - To assess intravenous fluid requirement and/or hospitalization for dehydration secondary to diarrhea between control observation period and active Enterade® period. - To evaluate difference in utilization of standard-of-care anti-diarrheal medications between control observation period and Enterade® period. - To compare subjective feeling of bloating and flatulence before and after administration of Enterade®. - To evaluate changes in patient weight before and after administration of Enterade®.

NCT ID: NCT03220087 Completed - Clinical trials for Neuroendocrine Tumors

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain

RECOSY
Start date: July 21, 2017
Phase:
Study type: Observational

The objective of this study is to describe the use of resources and the costs associated with controlled or uncontrolled CS in patients with NETs in Spain.

NCT ID: NCT03183271 Completed - Clinical trials for Neuroendocrine Tumors

Proton Boost for Locally Advanced HEAD AND NECK TUMORS

Start date: July 16, 2012
Phase: N/A
Study type: Interventional

The aim of this research project is to test the local response and the acute toxicity (which can be observed within 90 days).

NCT ID: NCT02826928 Completed - Clinical trials for Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

Start date: October 26, 2016
Phase: N/A
Study type: Interventional

Urinary measure of 5-hydroxyindolacetic acid (5HIAA) is an important marker for the diagnosis and follow-up of patients with small-intestine neuroendocrine tumors. Although this marker has good specificity, its sensitivity is moderate and its dosage is constraining, since it requires urine collection over 2-3 days and specific diet. Preliminary data suggested that overnight 5HIAA value may be representative of 24-hour 5HIAA value, and that plasma 5HIAA dosage could be a valuable alternative to urine 5HIAA dosage. The main objective of this study is to compare sensitivity and specificity of overnight 5HIAA value, 24-hour 5HIAA value and plasma 5HIAA value, in patients with small-intestine neuroendocrine tumors.

NCT ID: NCT02685553 Completed - Clinical trials for Pancreatic Neuroendocrine Tumors

Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project

Start date: February 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the use of Near-Infrared Technology can guide the laparoscopic resection of hypervascular neoplasms of the pancreas.

NCT ID: NCT02575300 Completed - Carcinoid Tumors Clinical Trials

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Start date: October 9, 2015
Phase: Phase 2
Study type: Interventional

This is a prospective phase II open-label trial, stratifying patients equally into two cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs). The purpose of this study is to test any good and bad effects of the study drug called Ibrutinib. The study population will consist of adult patients with histologically confirmed low to intermediate grade NETs of the GI tract, lungs and unknown primary (carcinoid tumors) or pNETs. All patients must be confirmed to have advanced disease. The study will enroll up to 51 patients in two cohorts (30 carcinoid and 21 pNET patients).

NCT ID: NCT02539433 Completed - Clinical trials for Neuroendocrine Tumors

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Start date: December 2003
Phase: N/A
Study type: Interventional

Imaging of neuroendocrine (NETs), such as carcinoids and pheochromocytomas (PHEOs), is suboptimal, limiting curative treatment. The investigators wanted to explore the use of PET and F-DOPA i.v. for the localization of these types of neoplasms. The investigators used a similar protocol as they had used for PET (Positron emission tomography) or FDG (Fludeoxyglucose) imaging in oncologic patients. F-DOPA, prepared according to United States Pharmacopeia (USP) guidelines, was approved by the North Shore University Hospital Radiation Safety Committee in 1989 and 1994 for the study of neurological diseases and used uneventfully.